Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Frey, Noelle V., Shaw, Pamela A., Hexner, Elizabeth O., Pequignot, Edward, Gill, Saar, Luger, Selina M., Mangan, James K., Loren, Alison W., Perl, Alexander E., Maude, Shannon L., Grupp, Stephan A., Shah, Nirav N., Gilmore, Joan, Lacey, Simon F., Melenhorst, Jos J., Levine, Bruce L., June, Carl H., Porter, David L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8312030/
https://ncbi.nlm.nih.gov/pubmed/31815579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01892
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky